The Clinical Features and Pregnancy Outcomes of CTD Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Prednisone: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Hydroxychloroquine: 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Aspirin: 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
low molecular weight heparin Enoxaparin: 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
Study summary
Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on. APS is caused by autoimmune disorders that cause recurrent miscarriage, thrombosis, and thrombocytopenia, and often secondary to connective tissue diseases such as SLE. Undifferentiated connective tissue disease (UCTD) is currently considered to be an independent disease in the classification of CTD. And women of childbearing age who suffer UCTD is more common than that in other definite CTDs. Therefore, the impact of the disease flare and the influence of medicine on pregnancy and lactation are important for these patients who may suffer high-risk of abnormal pregnance.
Eligibility
Primary outcome measure(s)
- Live birth rate — After 28 weeks of gestation
Percentage of all patients that lead to live birth after 28 weeks of gestation
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Qilu Hospital | Jinan | Shandong | Recruiting |
On this site
📄 Deltasone (prednisone) drug profile →More Qilu Hospital of Shandong University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04918524 on ClinicalTrials.gov ↗ ← All trials in China